BRAND NAME

GENERIC NAME

CLASSIFICA -TION

ACTION

INDICATION

CONTRAIN DICATION

Apoferrous Ferrous sulfate Gluconate2 ; ApoFerrous Sulfate3; DexFerrum 4 ; DexIron4; Femiron1; Feosol Caplets3; Feosol Tablets3; Feostat1; Feostat Drops1; Fer-In-Sol Drops3; Fer-In-Sol Syrup3; Fer-Iron Drops3; Fer-gensol3; Feratab3

Anti anemic, Iron supplement

Elevates the serum iron concentratio n which then helps to form High or trapped in the reticuloendot helial cells for storage and eventual conversion to a usable form of iron.

Iron deficiency anemia, hemodialysisinduced (treatment) Sodium ferric gluconate complex injection and iron sucrose injection are indicated for the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy. Iron deficiency

Hypersensiti vity Severe hypotension.

SIDE EFFECTS/ ADVERSE EFFECTS Dizziness N&V Nasal Congestion Dyspnea Hypotensio n CHF MI Muscle cramps Flushing checking with physician if black stools occur with other symptoms of internal blood loss Signs of potential side effects, especially

DOSAG E

NURSING RESPONSIBILITY

Initial: 300 to 325 mg of regularrelease ferrous sulfate orally once a day.

Advise patient to take medicine as prescribed. Caution patient to make position changes slowly to minimize orhtostatic hypotension. Instruct patient to avoid concurrent use of alcohol or OTC medicine without consulting the physician. Advise patient to consult physician if irregular heartbeat, dyspnea, swelling of hands and feet and hypotension occurs. Inform patient that angina attacks may occur 30 min.

anemia (prophylaxis and treatment) Iron supplements are indicated in the prevention and treatment of iron deficiency anemia, which may result from inadequate diet, malabsorptio n, pregnancy, rapid growth during childhood, and/or blood loss. Iron dextran and iron sorbitol are recommende d for patients in whom iron deficiency has been

abdominal or stomach pain , cramping, or soreness, allergic reaction, backache, flank, groin, or muscle pain, chills, dizziness, fever with increased sweating, headache, metallic taste, nausea or vomiting, numbness, pain, or tingling of hands or feet, chest pain, hypotensio n, fast heartbeat, flushing or redness of skin, pain

after administration due reflex tachycardia. Encourage patient to comply with additional intervention for hypertension like proper diet, regular exercise, lifestyle changes and stress management.

determined, only after the cause has been corrected, if possible, and only when oral administratio n has been found unsatisfactory or impossible.

and redness or sores at intramuscul ar injection site, redness at intravenous injection site, contact irritation in alimentary tract, diplopia, malaise, or weakness

BRAND NAME

GENERIC NAME

CLASSIFICA -TION

ACTION

INDICATION

CONTRAIN DICATION Hypersensit ivity. Crosssensitivity may exist among phenothiazin

thorazine

chlorproma zine

Antipsychotic s

Block dopamine receptors in the brain; also alter dopamine

Acute and chronic psychoses, particularly when accompanied by increased

SIDE EFFECTS/ ADVERSE EFFECTS CNS: neuroleptic malignant syndrome, sedation, extrapyrami dal

DOSAG E

NURSING RESPONSIBILITY

PO 1025mg 2=4 times daily; may

Assess mental status prior to and periodically during therapy. Monitor BP and pulse prior to and frequently during

release and turnover. Prevention of seizures

psychomotor activity. Nausea and vomiting. Also used in the treatment of intractable hiccups.

es. Should not be used in narrowangle glaucoma. Should not be used in patients who have CNS depression.

reactions, tardive dyskinesia CV: hypotensio n (increased with IM, IV) EENT: blurred vision, dry eyes, lens opacities GI: constipatio n, dry mouth, anorexia, hepatitis, ileus GU: urinary retention Hematologi c: agranulocyt osis, leukopenia Skin: photosensit ivity, pigment

increase every 3-4 days (usual dose is 200ng/da y; up to 1g/day)

the period of dosage adjustment. May cause QT interval changes on ECG. Observe patient carefully when administering medication, to ensure that medication is actually taken and not hoarded. Monitor I&O ratios and daily eight. Assess patient for signs and symptoms of dehydration. Monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, pallor, tiredness, severe muscle

changes, rashes

stiffness, loss of bladder control. Report symptoms immediately. May also cause leukocytosis, elevated liver function tests, elevated CPK. Advise patient to take medication as directed. Take missed doses as soon as remembered, witih remaining doses evenly spaced through out the day. May require several weeks to obtain desired effects. Do not increase dose or discontinue medication without consulting health care professional. Abrupt withdrawal may cause dizziness, nausea, vomiting, GI upset, trembling, or uncontrolled

movements of mouth, tongue or jaw.